# Bacteremia: Interpreting GenMark ePlex® Results – VASP

## Background

- When BCx turn positive, the lab reports Gram stain and GenMark
    ePlex® results to help guide empiric therapy, while awaiting further
    species identification and susceptibilities.

## Management

- Start empiric antibiotic therapy (based on clinical picture and
    table below)

- Consider ordering repeat BCx x2 based on organism to document
    clearance
    - Repeat for: *Staph* (MRSA or MSSA), *Strep lugdunensis*
    - If source control & no endovascular infxn, no need to repeat (most
    other strep and GNR’s)

- [VUMC
    antibiograms](https://www.vumc.org/antimicrobial-stewardship-program/antibiograms)
    can be used to reference typical resistance patterns and most common
    organisms in blood cultures.

- *Candida* in a blood culture is NEVER considered a contaminant

GRAM POSITIVE COCCI 

<table>
<colgroup>
<col style="width: 37%" />
<col style="width: 28%" />
<col style="width: 34%" />
</colgroup>
<thead>
<tr class="header">
<th><blockquote>
<p>Organism</p>
</blockquote></th>
<th><blockquote>
<p>Resistance Marker</p>
</blockquote></th>
<th><blockquote>
<p>Preliminary Recommendation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td rowspan="2"><p><em>Staphylococcus aureus</em></p>
<blockquote>
<p>or</p>
</blockquote>
<p><em>Staphylococcus lugdunensis</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td>No mecA detected</td>
<td><p>Start nafcillin or cefazolin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Staphylococcus epidermidis</em></p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start therapy if uncertain</p></td>
<td>mecA detected</td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td>No mecA detected</td>
<td><p>Start nafcillin or cefazolin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td><p>Other coagulase negative <em>Staph</em></p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start abx if uncertain</p></td>
<td></td>
<td>Start vancomycin IV</td>
</tr>
<tr class="even">
<td><em>Streptococcus: agalactiae, pyogenes, anginosus</em></td>
<td></td>
<td><p>Start penicillin IV or CTX IV</p>
<p>Stop empiric vancomycin</p></td>
</tr>
<tr class="odd">
<td><em>Streptococcus pneumoniae</em></td>
<td></td>
<td><p>Start ceftriaxone</p>
<p>Stop empiric vancomycin</p>
<p>Await PCN sensitivity data</p></td>
</tr>
<tr class="even">
<td><p>Other <em>Streptococcus</em></p>
<p>-May be contaminant</p></td>
<td></td>
<td><p>Start ceftriaxone</p>
<p>Stop empiric vancomycin</p>
<p>Await PCN sensitivity data</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Enterococcus faecalis</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>vanA or vanB detected</td>
<td><p>Start daptomycin 8-10mg/kg/day IV</p>
<p>Don’t treat w vancomycin IV</p>
<p>Contact precautions</p></td>
</tr>
<tr class="even">
<td>No vanA or vanB</td>
<td><p>Start ampicillin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="odd">
<td rowspan="2"><p><em>Enterococcus faecium</em></p>
<p><strong>ID Consult REQUIRED</strong></p></td>
<td>vanA or vanB detected</td>
<td><p>Start daptomycin 8-10mg/kg/day IV</p>
<p>Don’t treat w vancomycin IV</p>
<p>Contact precautions</p></td>
</tr>
<tr class="even">
<td>No vanA or vanB</td>
<td><p>Start vancomycin IV</p>
<p>Follow-up ampicillin sensitivities</p></td>
</tr>
<tr class="odd">
<td colspan="2"><p><em>Micrococcus</em></p>
<p>-Often if in a single blood culture is skin contaminant</p></td>
<td><p>Repeat BCx</p>
<p>Start vancomycin IV if uncertain</p></td>
</tr>
</tbody>
</table>

GRAM POSITIVE RODS

<table>
<colgroup>
<col style="width: 46%" />
<col style="width: 53%" />
</colgroup>
<thead>
<tr class="header">
<th><blockquote>
<p>Organism</p>
</blockquote></th>
<th><blockquote>
<p>Preliminary Recommendation</p>
</blockquote></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em>Listeria monocytogenes</em></td>
<td><p>Start ampicillin</p>
<p>Stop empiric vancomycin IV</p></td>
</tr>
<tr class="even">
<td><p>Other Gram positive rod (e.g. <em>Bacillus cereus, Corynebacterium,
Cutibacterium acnes, Lactobacillus</em>)</p>
<p>-Often skin contaminant</p>
<p>-Repeat cultures, start therapy if uncertain</p></td>
<td><p>Start vancomycin IV</p>
<p>Follow-up sensitivities; some GPRs are resistant to
vancomycin</p></td>
</tr>
</tbody>
</table>

GRAM NEGATIVE RODS \*Consult ID if carbapenem resistance detected\*

<table>
<colgroup>
<col style="width: 29%" />
<col style="width: 70%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Organism</strong></th>
<th><strong>Preliminary Recommendation</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><em>Acinetobacter baumannii</em></td>
<td>Start ampicillin/sulbactam</td>
</tr>
<tr class="even">
<td><em>Bacteroides fragilis</em></td>
<td><p>Start metronidazole</p>
<p>If polymicrobial infection, piperacillin/tazobactam,
ampicillin/sulbactam, or meropenem based on other organisms</p>
<p>Do NOT double cover anaerobes</p></td>
</tr>
<tr class="odd">
<td><em>Citrobacter spp.</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Cronobacter sakazakii</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Enterobacter (non-cloacae complex)</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Enterobacter cloacae complex</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Escherichia coli</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><p><em>Fusobacterium nucleatum</em></p>
<p><em>Fusobacterium necrophorum</em></p></td>
<td>Start ampicillin/sulbactam or start/continue metronidazole</td>
</tr>
<tr class="odd">
<td><em>Haemophilus influenzae</em></td>
<td>Start/continue ceftriaxone</td>
</tr>
<tr class="even">
<td><em>Klebsiella oxytoca</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="odd">
<td><em>Klebsiella pneumoniae group</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><em>Morganella morganii</em></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="odd">
<td><em>Neisseria meningitidis</em></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="even">
<td><p><em>Proteus spp.</em></p>
<p><em>Proteus mirabilis</em></p></td>
<td>Continue empiric coverage and await susceptibilities</td>
</tr>
<tr class="odd">
<td><em>Pseudomonas aeruginosa</em></td>
<td>Start/continue cefepime or piperacillin-tazobactam</td>
</tr>
<tr class="even">
<td><em>Salmonella spp</em></td>
<td>Start/continue ceftriaxone</td>
</tr>
<tr class="odd">
<td><p><em>Serratia spp.</em></p>
<p><em>Serratia marcescens</em></p></td>
<td>Start/continue cefepime</td>
</tr>
<tr class="even">
<td><em>Stenotrophomonas maltophilia</em></td>
<td>Start trimethoprim-sulfamethoxazole (15-20mg/kg/day divided q8h for
normal renal function)</td>
</tr>
<tr class="odd">
<td colspan="2">Gram-Negative Resistance Genes</td>
</tr>
<tr class="even">
<td>CTX-M Positive (ESBL)</td>
<td><p>Start meropenem</p>
<p>Consider an Infectious Diseases consult</p>
<p>Contact precautions (see Infection Prevention website)</p></td>
</tr>
<tr class="odd">
<td><p>IMP Positive</p>
<p>KPC Positive</p>
<p>NDM Positive</p>
<p>OXA (OXA-23 and OXA-48) Positive</p>
<p>VIM Positive</p></td>
<td><p>Carbapenemase-producing organism</p>
<p>Obtain Infectious Disease consultation</p>
<p>Contact precautions (see Infection Prevention website)</p></td>
</tr>
</tbody>
</table>
